Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
US OptionsDetailed Quotes
RARE250516P22500
- 0.00
- 0.000.00%
15min DelayClose May 2 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover0.00%IV42.75%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma18.28Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Ultragenyx Pharmaceutical Newsroom
8 Health Care Stocks Whale Activity In Today's Session
Earnings Preview: RARE to Report Financial Results Post-market on May 06
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Barclays
Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $80
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $80
BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating
Ukrainian Minister Announces 'Significant Progress' in Minerals Deal Talks With US
Wedbush Maintains Ultragenyx Pharmaceutical(RARE.US) With Hold Rating, Cuts Target Price to $39
Express News | Ultragenyx Pharmaceutical Inc : Wedbush Cuts Target Price to $39 From $47
US Lowers Estimate of Aid Provided to Ukraine to $100 Billion - Report
Sector Update: Health Care
Sector Update: Health Care Stocks Gain in Afternoon Trading
AI-focused Drug Discovery Firms Rise as FDA Phases Out Animal Testing
US FDA Animal Testing De-Emphasis May Boost Biotech Innovation, RBC Says
Insiders Could Have Profited By Holding Onto Ultragenyx Pharmaceutical Shares Despite 12% Drop
Truist Financial Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
Market Insights
Discussing
BRK cash at new high: What to expect from Buffett’s meeting?
🎙️Discussion 1. Buffett said he won't sell Japanese stocks for the next ten years. What's your take? 2. In the face of market changes, do y
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
